Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2021-04-16 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于灵康药业集团股份有限公司2020年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. regarding the 2020 annual verification opinion on the deposit and use of raised funds by Lingkang Pharmaceutical Group Co., Ltd. It includes specific financial data on the amounts raised in 2015 and 2020, the use and balance of these funds, compliance with regulatory requirements, and audit opinions from an accounting firm. The document contains tables with actual financial figures, descriptions of fund management, and audit verification, indicating it is a substantive financial and compliance report rather than a brief announcement or certification. The presence of detailed financial data and audit opinions related to the use of raised funds aligns with the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2020
2021-04-16 Chinese
关于召开2020年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2020 Annual General Meeting (AGM) of Lingkang Pharmaceutical Group Co., Ltd. It includes details such as the date, voting methods, meeting agenda, and instructions for shareholders to participate and vote. It does not contain the actual annual report, financial statements, or voting results, but rather the announcement and procedural information for the AGM. The document length is 3449 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2021-04-16 Chinese
公司董事会审计委员会2020年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020 Annual Performance Report of the Board Audit Committee" and details the audit committee's activities, including oversight of the 2019 annual report audit, quarterly and semi-annual reports, and internal control evaluations. It references compliance with regulatory standards and audit procedures but does not contain full financial statements or comprehensive financial data itself. The document is a report on the audit committee's work and audit supervision rather than the full annual report or standalone audit report. Given the focus on audit committee activities and oversight, this fits best under the category of Audit Report / Information (AR). The document length is 1617 characters, which is consistent with a detailed committee report rather than a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2020
2021-04-16 Chinese
独立董事关于第三届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion report from the independent directors of Lingkang Pharmaceutical Group Co., Ltd. regarding various matters discussed at the 13th meeting of the third board of directors held on April 15, 2021. It includes opinions on the 2020 profit distribution plan, reappointment of the audit firm for 2021, a special report on the use of raised funds in 2020, internal control evaluation report for 2020, application for comprehensive credit lines for 2021, expected related party transactions for 2021, and cash management of idle funds. The document references regulatory guidelines and company bylaws but does not contain full financial statements or detailed financial data. It is a formal board/management related document expressing independent directors' opinions on board matters and proposals to be submitted to the shareholders' meeting. The length is 2279 characters, which is relatively short and focused on board opinions rather than a full annual report or audit report. Therefore, the best classification is Board/Management Information (MANG).
2021-04-16 Chinese
关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual deposit and usage of raised funds by Lingkang Pharmaceutical Group Co., Ltd. It includes specific data on funds raised through IPO and convertible bonds, their management, usage, balances, and compliance with regulatory requirements. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange rules, and includes detailed tables of fund usage and project status. The content focuses on the management and use of capital raised, rather than financial performance or earnings. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 7,000 characters and contains substantive financial data related to capital usage, not just an announcement or summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2021-04-16 Chinese
2021年第一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2021. The report is unaudited as stated in the text. The length of the document is substantial (15,000 characters), and it includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and the content is substantive financial data and analysis. Therefore, the correct classification is IR with high confidence. Q1 2021
2021-04-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.